The report, now available on ASDReports, recognizes the following companies as the key players in the Global Rheumatoid Arthritis Drugs Market: AbbVie, Amgen, Bristol-Myers Squibb (BMS), Johnson & Johnson, Pfizer and F. Hoffmann-La Roche
Other Prominent Vendors in the market are: Ablynx, Alder BioPharmaceuticals, Antares Medical Services, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Morphotek, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Takeda Pharmaceuticals, UCB and Vertex Pharmaceuticals.
Commenting on the report, an analyst said: “It is expected that the availability of patient assistance programs from governmental and non-governmental organizations to bode well for the market. These programs help decrease the churn out rate of the patients seeking treatment by reducing the out-of-pocket expenditure of consumers.”
According to the report, the number of older people with RA due to age-related joint disorders is rising in both developing and developed countries. This is expected to create more demand for RA drugs. The market dominance of biologics is also expected to drive market growth during the forecast period.
Further, the report states that the high cost of treatments for RA; however, hinders the acceptability of available treatments among patients.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.